Accession Number : ADA595679


Title :   Augmenting Trastuzumab Therapy Against Breast Cancer Through Selective Activation of NK Cells


Descriptive Note : Annual summary 30 Sep 2012-29 Sep 2013


Corporate Author : STANFORD UNIV CA


Personal Author(s) : Kohrt, Holbrook


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a595679.pdf


Report Date : Oct 2013


Pagination or Media Count : 26


Abstract : Trastuzumab, a monoclonal antibody (mAb) targeting HER-2/neu, kills tumor cells by several mechanisms, including antibody-dependent cellular cytotoxicity (ADCC). Strategies that enhance the activity of ADCC effectors, including natural killer (NK) cells, may improve trastuzumab s efficacy. NK cells that encounter trastuzumab-coated, HER2-overexpressing breast cancer cells become activated and express CD137, a costimulatory receptor. CD137 activation, which is dependent on the Fc RIII receptor, occurred both in vitro and in the peripheral blood of women with HER2- expressing breast cancer following trastuzumab treatment. Stimulation of trastuzumab-activated NK cells with an agonistic mAb against CD137 killed breast cancer cells more efficiently in vitro and in multiple HER2+ in vivo models.


Descriptors :   *BREAST CANCER , ANTIBODIES , BLOOD , CELLS(BIOLOGY) , CYTOTOXINS , MONOCLONAL ANTIBODIES , SENSE ORGANS , THERAPY


Subject Categories : Anatomy and Physiology
      Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE